Brief Correspondence

Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma

Eduard Roussel\textsuperscript{a}, Lisa Kinget\textsuperscript{b}, Annelies Verbiest\textsuperscript{b}, Jessica Zucman-Rossi\textsuperscript{c}, Bram Boeckx\textsuperscript{d,e}, Steven Joniau\textsuperscript{a}, Diether Lambrechts\textsuperscript{d,e}, Maarten Albersen\textsuperscript{a,*}, Benoit Beuselinck\textsuperscript{b}

Abstract

Highly effective systemic treatments have globally improved outcomes in metastatic clear-cell renal cell carcinoma (m-ccRCC). However, despite many efforts, reliable biomarkers predicting individual responses are currently lacking. Moreover, mixed responses are commonly observed. We hypothesized that molecular heterogeneity between primary tumors and their metastases could flaw biomarker research based on features of the primary tumor and explain mixed responses. Therefore, we studied the heterogeneity of the ccrcc1–4 molecular subtypes across patient-matched primary and metastatic lesions over time in 62 patients with m-ccRCC who underwent both nephrectomy and metastasectomy. These subtypes characterize underlying disease biology and are associated with outcomes in both the primary and metastatic settings. We observed a concordance rate of 58% (95% confidence interval 45–71%). This concordance was not affected by the interval between nephrectomy and resection of the metastatic lesion. Across discordant pairs, the metastatic lesions mostly exhibited a less favorable molecular subtype. Moreover, primary tumors with the favorable ccrcc2 molecular subtype were characterized by favorable prognosis and a long interval between nephrectomy and metastasectomy. Conversely, tumors with the unfavorable ccrcc4 molecular subtype relapsed quickly and had poor prognosis. Thus, the considerable molecular heterogeneity between patient-matched m-ccRCC primary and metastatic lesions provides an explanation for mixed responses to systemic therapy and could impact the development of biomarker studies in which the primary tumor is often considered a surrogate for metastatic disease.

Patient summary: We studied primary tumors and metastases from patients with kidney cancer and found considerable heterogeneity in their molecular features. This heterogeneity explains mixed responses to systemic therapy and is important to take into account in future biomarker studies for this disease.

In recent years, novel and highly effective systemic treatments for metastatic clear-cell renal cell carcinoma (m-ccRCC) have revolutionized the treatment landscape and globally improved outcomes for patients [1]. However,
of the primary tumors, 13 (21.0%) were ccrcc1, 40 (64.5%) were ccrcc2, one (1.6%) was ccrcc3, and eight (12.9%) were ccrcc4. Fig. 1 shows a swimmer plot depicting the resected metastases over time and their ccrcc molecular subtypes. Clearly, patients with a primary tumor of the favorable ccrcc2 subtype are characterized by a clinical disease course with long overall survival (median 74 mo) and a long interval between resection of the primary tumor and of the metastatic lesion(s) (median 19 mo). Conversely, patients with a ccrcc4 primary tumor had poor overall survival (median 20 mo) and a short time between resection of the primary and the metastasis (median 0 mo). We calculated the ccrcc molecular subtype concordance between the primary tumor and the first resected metastasis. If multiple metastases resected at the same time point had discrepant molecular subtypes, the observation was considered discordant. The 95% confidence intervals (CIs) were calculated using the Clopper-Pearson exact method.

Out of the 62 pairs, 36 (58%) were concordant (95% CI 45–71%). Out of the 26 discordant pairs, 18 (69.2%) switched to a more unfavorable subtype in at least one of the resected metastases, while six (23.1%) switched to a more favorable subtype and two (7.7%) switched between the ccrcc2 and ccrcc3 subtypes, which both have favorable prognosis. The fact that discordant subtypes more often switch to a more aggressive subtype is in line with the Serie study which reported a switch from the favorable cca to the unfavorable ccB subtype in 80% of discordant cases.

However, concordance analysis does not consider the effect of time. To assess whether the concordance rate depends on the time between resection of the primary tumor and the metastasis, we performed logistic regression with molecular subtype concordance between the primary tumor and the first resected metastasis over time.

We collected archived formalin-fixed, paraffin-embedded (FFPE) tissue specimens from 62 patients with m-ccRCC who underwent nephrectomy at our institution between 1998 and 2018 and who had tissue available from both the primary tumor and at least one metastasis. We performed whole-transcriptome RNA sequencing to determine the ccrcc molecular subtypes for the 62 primary tumors and 121 metastases as previously described [3,4]. Of note, all metastasis tissue was obtained via surgical metastasectomy, which entails a general selection bias towards patients with more favorable characteristics [8].

The baseline characteristics of our cohort are shown in Table 1. Of the primary tumors, 13 (21.0%) were ccrcc1, 40 (64.5%) were ccrcc2, one (1.6%) was ccrcc3, and eight (12.9%) were ccrcc4. Of the 121 metastases, while six (23.1%) switched to a more favorable subtype and two (7.7%) switched between the ccrcc2 and ccrcc3 subtypes, which both have favorable prognosis. The fact that discordant subtypes more often switch to a more aggressive subtype is in line with the Serie study which reported a switch from the favorable cca to the unfavorable ccB subtype in 80% of discordant cases.

However, concordance analysis does not consider the effect of time. To assess whether the concordance rate depends on the time between resection of the primary tumor and the metastasis, we performed logistic regression with molecular subtype concordance between the primary tumor and the first resected metastasis over time.

### Table 1 – Baseline characteristics

| Parameter | Result |
|-----------|--------|
| Patients (n) | 62 |
| Median age at nephrectomy, yr (interquartile range) | 62 (53–67) |
| Male, n (%) | 44 (71.0) |
| Synchronous metastases at nephrectomy, n (%) | 27 (43.6) |
| Median number of metastases resected, n (interquartile range) | 1 (1–2) |
| Molecular subtype of the primary tumor, n (%) | |
| ccrcc1 | 13 (21.0) |
| ccrcc2 | 40 (64.5) |
| ccrcc3 | 1 (1.6) |
| ccrcc4 | 8 (12.9) |
| Metastases (n) | 121 |
| Molecular subtype of metastases, n (%) | |
| ccrcc1 | 12 (9.9) |
| ccrcc2 | 66 (54.6) |
| ccrcc3 | 5 (4.1) |
| ccrcc4 | 38 (31.4) |
| Location of resected metastases, n (%) | |
| Lung | 32 (26.5) |
| Nonregional lymph nodes | 32 (26.5) |
| Contralateral kidney | 10 (8.3) |
| Contralateral adrenal gland | 10 (8.3) |
| Bone | 10 (8.3) |
| Pancreas | 6 (5.0) |
| Brain | 4 (3.3) |
| Thyroid | 4 (3.3) |
| Gingiva | 3 (2.5) |
| Iliopsoas | 3 (2.5) |
| Skin | 3 (2.5) |
| Intestine | 2 (1.7) |
| Liver | 2 (1.7) |
| Pleura | 2 (1.7) |
| Gall bladder | 1 (0.8) |
| Ovary | 1 (0.8) |
| Ureter | 1 (0.8) |
| Peritoneal | 1 (0.8) |
| Epidural | 1 (0.8) |
tumor and metastasis as the dependent variable and time as the independent variable. This showed no significant impact of the time to the first metastasectomy on the concordance (odds ratio 1.0, 95%CI 0.98–1.01; \( p = 0.79 \)).

We did not assess molecular heterogeneity within the same primary tumor in our study, which poses an additional challenge for routine use of tissue-based biomarkers. This issue might be addressed in the future with the use of imaging-based biomarkers, providing whole-tumor virtual biopsies [9]. Moreover, it has been shown that tumors with higher intratumoral heterogeneity often exhibit a disease course that is characterized by attenuated progression and gradual acquisition of metastatic competence [10]. Conversely, primary tumors with low intratumoral heterogeneity and a monoclonal structure often exhibit rapid disease progression to multiple disease sites.

Thus, while our study is limited by the long time period for patient inclusion, the fact that all patients included underwent both nephrectomy and metastasectomy provides more granular data on the considerable heterogeneity between primary tumors and matched metastases from ccRCC. This heterogeneity might provide an explanation for mixed responses to systemic therapy. Moreover, this is an important consideration for the development of biomarker studies in which the primary tumor is considered a surrogate for metastatic lesions and our findings underscore the value of tissue sampling of metastatic sites if tissue-based biomarkers might direct therapeutic decision-making in the future.

**Author contributions:** Eduard Roussel had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Roussel, Beuselinck.

Acquisition of data: Roussel, Verbiest, Kinget, Beuselinck.

Analysis and interpretation of data: Roussel.

Drafting of the manuscript: Roussel.

Critical revision of the manuscript for important intellectual content: Roussel, Kinget, Verbiest, Zucman-Rossi, Boeckx, Joniau, Lambrechts, Albersen, Beuselinck.
References

[1] Demasure S, Spriet I, Debruyne PR, et al. Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta Oncol 2021;61:22–9. https://doi.org/10.1080/0284186X.2021.1989720.

[2] Beuselinck B, Job S, Becht E, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res 2015;21:1329–39. https://doi.org/10.1158/1078-0432.CCR-14-1128.

[3] Roussel E, Verbiest A, Kinget L, et al. Molecular subtypes and gene expression signatures as prognostic features in fully resected clear cell renal cell carcinoma: a tailored approach to adjuvant trials. Clin Genitourin Cancer 2021;19:E382–94. https://doi.org/10.1016/j.clgc.2021.07.005.

[4] Roussel E, Kinget L, Verbiest A, et al. Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. Acta Oncol 2021;60:1499–506. https://doi.org/10.1080/0284186X.2021.1962971.

[5] Verbiest A, Couchy G, Job S, et al. Molecular subtypes of clear-cell renal cell carcinoma are prognostic for outcome after complete metastasectomy. Eur Urol 2018;74:474–80. https://doi.org/10.1016/j.euro.2018.01.042.

[6] Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell 398 renal cell carcinoma by consensus clustering reveals distinct subtypes and survival 399 patterns. Genes Cancer 2010;1:152–63.

[7] Serie DJ, Joseph RW, Cheville JC, et al. Clear cell type A and B molecular subtypes in metastatic clear cell renal cell carcinoma: tumor heterogeneity and aggressiveness. Eur Urol 2017;71:979–85. https://doi.org/10.1016/j.euro.2016.11.018.

[8] Verbiest A, Roussel E, Tosco L, et al. Long-term outcomes in clear-cell renal cell carcinoma patients treated with complete metastasectomy. Kidney Cancer 2020;4:177–83. https://doi.org/10.3233/KCA-200093.

[9] Roussel E, Capitanio U, Kutikov A, et al. Novel imaging methods for renal mass characterization: a collaborative review. Eur Urol. In press. https://doi.org/10.1016/j.euro.2022.01.040.

[10] Turajlic S, Xu H, Litchfield K, et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell 2018;173:581–594.e12. https://doi.org/10.1016/j.cell.2018.03.057.

* Department of Urology, University Hospitals Leuven, Leuven, Belgium

b Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium

c Inserm UMR-1162, Génomique fonctionnelle des tumeurs solides, Institut Universitaire Hématologie, Paris, France

d Laboratory of Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium

e VIB Center for Cancer Biology, Leuven, Belgium

* Corresponding author. Department of Urology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Tel. +32 16 346930. E-mail address: maarten.albersen@uzleuven.be (M. Albersen).